Bone Cancer Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 1.22 Billion |
| Market Size (2029) | USD 1.58 Billion |
| CAGR (2024 - 2029) | 5.27 % |
| Fastest Growing Market | North America |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Bone Cancer Treatment Market Analysis
The Bone Cancer Treatment Market size is estimated at USD 1.22 billion in 2024, and is expected to reach USD 1.58 billion by 2029, growing at a CAGR of 5.27% during the forecast period (2024-2029).
During the early stages of COVID-19, there was a significant reduction in the number of cases treated in the musculoskeletal oncology departments, which has affected the number of surgical volumes. The massive reduction in musculoskeletal oncology services may have drastic consequences for affected patients and the overall market growth. However, several precautionary guidelines were issued by the respective government authorities to initiate the delayed or postponed bone cancer treatments, enabling patients to acquire safe access to treatment during the COVID-19 pandemic.
Certain factors driving the market growth include the increasing global burden of bone cancer and government initiatives for bone cancer awareness. The incidence of bone cancer is on a steady rise and needs to be addressed at the earliest to reduce the burden of bone sarcoma across the world.
According to estimates by the American Society of Clinical Oncology, the United States is estimated to witness 3,610 new cases of bone cancer and an expected 2,060 deaths due to bone cancer in 2021. The chemotherapeutic drugs approved for the treatment of bone cancer do not have an effective treatment regime, as it always varies according to the prevailing conditions and the way the patient's body responds to the drug. Hence, the associated side effects, risks, and limitations of the treatment are limiting the growth of the bone cancer treatment drug market.
Bone Cancer Treatment Market Trends
This section covers the major market trends shaping the Bone Cancer Treatment Market according to our research experts:
Osteosarcoma is Expected to Hold the Largest Share Over the Forecast Period
The COVID-19 pandemic has disrupted surgical procedures, chemotherapy timings, and frequent hospital visits. In addition, a radical change in the osteosarcoma surgical plan was also observed due to the COVID-19 pandemic. In the bone cancer segment of the market, among all primary bone cancers, osteosarcoma is expected to have the largest market size over the forecast period.
Osteosarcoma is the most common type of cancer affecting the bones, and it mostly occurs in children and young adults. Based on the cells, osteosarcoma is classified as high-, intermediate-, and low-grade. According to the American Cancer Society, 2019, about 800 to 900 new cases of osteosarcoma are diagnosed in the United States every year, with about half of these occurring in children and teenagers.
Research on osteosarcoma is done at various medical centers, university hospitals, and other institutions across the world. Many advancements have taken place in the treatment of osteosarcoma in the past few decades. Osteosarcoma can be treated by surgery, radiation therapy, chemotherapy, targeted therapy drugs, etc.
Thus, research related to the bone cancer treatment market is increasing, owing to the high prevalence of osteosarcoma globally.
North America Dominates the Market, and It is Expected to do the Same During the Forecast Period
In North America, the COVID-19 pandemic largely affected the US region, which led to disruptions in many surgical procedures. However, currently, the surgical procedures are being carried out with precautionary measures, which will further lead to steady growth of the market.
North America currently dominates the bone cancer treatment market, and it is expected to continue its stronghold for a few more years. According to the American Cancer Society estimates for 2022, around 3,910 new cases will be diagnosed, along with 2,100 deaths, due to bone cancer. The same source stated that primary bone cancers (cancers that start in the bones) are uncommon, accounting for less than 1% of all cancers. In adults, cancers that spread to the bones from other organs are much more common than primary bone cancers. Osteosarcoma is the most common type of primary bone cancer overall, followed by chondrosarcoma and Ewing sarcomas.
The region is expected to increase its market share in the future, owing to the fact that currently, in the region, mainly in the United States, many clinical trials are underway for bone cancer therapies. Some studies are testing new chemo drugs. Researchers are also looking for new ways to use the existing approved drug portfolio. For instance, doctors are studying whether adding a bisphosphonate called zoledronic acid (Zometa) to the bone cement, which is used in filling the space left after removing a giant cell tumor, may decrease the chances of that tumor returning to that place. In February 2020, Count Me In, a non-profit research initiative, launched the Osteosarcoma Project, a patient-partnered effort that enables people in the United States and Canada who have been affected by osteosarcoma to accelerate research. This is likely to boost the regional market growth over the forecast period.
Bone Cancer Treatment Industry Overview
The bone cancer treatment market is highly competitive and consists of a considerable number of significant players. All of the existing players in the market are either legacy suppliers of treatment options, like chemotherapy and radiation therapy, or are concentrating on clinical trials for novel bone cancer approaches, including targeted therapy and immunotherapy. Companies like Bayer AG, Amgen, Novartis AG, and Pfizer Inc., among others, are expected to hold substantial shares in the bone cancer treatment market.
Bone Cancer Treatment Market Leaders
Amgen
Bayer AG
Pfizer Inc.
Novartis International AG
Johnson and Johnson
*Disclaimer: Major Players sorted in no particular order
Bone Cancer Treatment Market News
- In December 2021, the FDA's Centers for Devices and Radiological Health granted a breakthrough device designation to ZetaMet technology for use in the treatment of metastatic bone cancers and osteologic interventions.
- In October 2020, Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals Inc. to offer further upside potential to various disorders such as infectious diseases and vaccines, neuroscience, oncology, and pulmonary hypertension.
Bone Cancer Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Bone Cancer
4.2.2 Increasing Government Initiatives for Bone Cancer Awareness
4.3 Market Restraints
4.3.1 Unavailability of Effective Treatment and Side Effects
4.3.2 High Cost of Cancer Therapies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 Bone Cancer Type
5.1.1 Primary Bone Cancer
5.1.1.1 Osteosarcoma
5.1.1.2 Chondrosarcoma
5.1.1.3 Ewing Tumor
5.1.1.4 Other Bone Cancer Types
5.1.2 Secondary Bone Cancer (Metastatic Bone Cancer)
5.2 Treatment Type
5.2.1 Chemotherapy
5.2.1.1 Doxorubicin
5.2.1.2 Cisplatin
5.2.1.3 Cyclophosphamide
5.2.1.4 Etoposide
5.2.1.5 Other Chemotherapies
5.2.2 Targeted Therapy
5.2.2.1 Denosumab
5.2.2.2 Imatinib
5.2.3 Radiation Therapy
5.2.4 Surgery
5.2.5 Other Treatments
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen
6.1.2 Baxter
6.1.3 Bayer AG
6.1.4 Hikma Pharmaceuticals
6.1.5 Johnson & Johnson
6.1.6 Novartis AG
6.1.7 Pfizer Inc.
6.1.8 Recordati Group
6.1.9 Takeda Pharmaceutical Company
6.1.10 Debiopharm
6.1.11 Eli Lilly and Company
6.1.12 Atlanthera
6.1.13 Spectrum Pharmaceuticals Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Bone Cancer Treatment Industry Segmentation
As per the scope, bone cancer refers to a malignant tumor that arises from cells of bones of the body. It is also known as primary bone cancer as it originates in the bones. Secondary bone cancer refers to a tumor that has spread to the bone area but originated elsewhere. In this report, a detailed analysis of the bone cancer treatment market is presented, with specific attention on primary bone cancer. The bone cancer treatment market is segmented by bone cancer type (primary bone cancer [osteosarcoma, chondrosarcoma, Ewing tumor, and other bone cancer types] and secondary bone cancer [metastatic bone cancer]), treatment type (chemotherapy, targeted therapy, radiation therapy, surgery, and other treatments), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across the major regions globally. The report offers the market size and forecasts in value (USD million) for the above segments.
| Bone Cancer Type | ||||||
| ||||||
| Secondary Bone Cancer (Metastatic Bone Cancer) |
| Treatment Type | |||||||
| |||||||
| |||||||
| Radiation Therapy | |||||||
| Surgery | |||||||
| Other Treatments |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Bone Cancer Treatment Market Research FAQs
How big is the Bone Cancer Treatment Market?
The Bone Cancer Treatment Market size is expected to reach USD 1.22 billion in 2024 and grow at a CAGR of 5.27% to reach USD 1.58 billion by 2029.
What is the current Bone Cancer Treatment Market size?
In 2024, the Bone Cancer Treatment Market size is expected to reach USD 1.22 billion.
Who are the key players in Bone Cancer Treatment Market?
Amgen, Bayer AG, Pfizer Inc., Novartis International AG and Johnson and Johnson are the major companies operating in the Bone Cancer Treatment Market.
Which is the fastest growing region in Bone Cancer Treatment Market?
North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Bone Cancer Treatment Market?
In 2024, the North America accounts for the largest market share in Bone Cancer Treatment Market.
What years does this Bone Cancer Treatment Market cover, and what was the market size in 2023?
In 2023, the Bone Cancer Treatment Market size was estimated at USD 1.16 billion. The report covers the Bone Cancer Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Bone Cancer Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Bone Cancer Treatment Industry Report
Statistics for the 2024 Bone Cancer Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Bone Cancer Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
